Transmembrane channel activity in human hepatocytes and cholangiocytes derived from induced pluripotent stem cells.
Journal
Hepatology communications
ISSN: 2471-254X
Titre abrégé: Hepatol Commun
Pays: United States
ID NLM: 101695860
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
revised:
06
01
2022
received:
09
09
2021
accepted:
22
01
2022
pubmed:
16
3
2022
medline:
29
6
2022
entrez:
15
3
2022
Statut:
ppublish
Résumé
The initial creation of human-induced pluripotent stem cells (iPSCs) set the foundation for the future of regenerative medicine. Human iPSCs can be differentiated into a variety of cell types in order to study normal and pathological molecular mechanisms. Currently, there are well-defined protocols for the differentiation, characterization, and establishment of functionality in human iPSC-derived hepatocytes (iHep) and iPSC-derived cholangiocytes (iCho). Electrophysiological study on chloride ion efflux channel activity in iHep and iCho cells has not been previously reported. We generated iHep and iCho cells and characterized them based on hepatocyte-specific and cholangiocyte-specific markers. The relevant transmembrane channels were selected: cystic fibrosis transmembrane conductance regulator, leucine rich repeat-containing 8 subunit A, and transmembrane member 16 subunit A. To measure the activity in these channels, we used whole-cell patch-clamp techniques with a standard intracellular and extracellular solution. Our iHep and iCho cells demonstrated definitive activity in the selected transmembrane channels, and this approach may become an important tool for investigating human liver biology of cholestatic diseases.
Identifiants
pubmed: 35289126
doi: 10.1002/hep4.1920
pmc: PMC9234678
pii: 02009842-202207000-00007
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1561-1573Subventions
Organisme : NCATS NIH HHS
ID : U01 TR002383
Pays : United States
Organisme : NIDDK NIH HHS
ID : UH3 DK119973
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK120531
Pays : United States
Organisme : NIDDK NIH HHS
ID : P01 DK096990
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK117881
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK078587
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK099257
Pays : United States
Informations de copyright
© 2022 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.
Références
Ye L, Swingen C, Zhang J. Induced pluripotent stem cells and their potential for basic and clinical sciences. Curr Cardiol Rev. 2013;9:63–72.
Takeishi K, Collin de l’Hortet A, Wang Y, Handa K, Guzman‐Lepe J, Matsubara K, et al. Assembly and function of a bioengineered human liver for transplantation generated solely from induced pluripotent stem cells. Cell Rep. 2020;31:107711.
Telias M, Ben‐Yosef D. Modeling neurodevelopmental disorders using human pluripotent stem cells. Stem Cell Rev Rep. 2014;10:494–511.
Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861–72.
Song Z, Cai J, Liu Y, Zhao D, Yong J, Duo S, et al. Efficient generation of hepatocyte‐like cells from human induced pluripotent stem cells. Cell Res. 2009;19:1233–42.
Sampaziotis F, Cardoso de Brito M, Madrigal P, Bertero A, Saeb‐Parsy K, Soares FAC, et al. Cholangiocytes derived from human induced pluripotent stem cells for disease modeling and drug validation. Nat Biotechnol. 2015;33:845–52.
Ogawa M, Ogawa S, Bear CE, Ahmadi S, Chin S, Li B, et al. Directed differentiation of cholangiocytes from human pluripotent stem cells. Nat Biotechnol. 2015;33:853–61.
De Assuncao TM, Sun Y, Jalan‐Sakrikar N, Drinane MC, Huang BQ, Li Y, et al. Development and characterization of human‐induced pluripotent stem cell‐derived cholangiocytes. Lab Invest. 2015;95:684–96.
Sampaziotis F, de Brito MC, Geti I, Bertero A, Hannan NR, Vallier L. Directed differentiation of human induced pluripotent stem cells into functional cholangiocyte‐like cells. Nat Protoc. 2017;12:814–27.
Collin de l’Hortet A, Takeishi K, Guzman‐Lepe J, Morita K, Achreja A, Popovic B, et al. Generation of human fatty livers using custom‐engineered induced pluripotent stem cells with modifiable SIRT1 metabolism. Cell Metab. 2019;30:e389.
Karagiannis P, Takahashi K, Saito M, Yoshida Y, Okita K, Watanabe A, et al. Induced pluripotent stem cells and their use in human models of disease and development. Physiol Rev. 2019;99:79–114.
Zabulica M, Srinivasan RC, Vosough M, Hammarstedt C, Wu T, Gramignoli R, et al. Guide to the assessment of mature liver gene expression in stem cell‐derived hepatocytes. Stem Cells Dev. 2019;28:907–19.
Takebe T, Wells JM. Organoids by design. Science. 2019;364:956–9.
Ouchi R, Togo S, Kimura M, Shinozawa T, Koido M, Koike H, et al. Modeling steatohepatitis in humans with pluripotent stem cell‐derived organoids. Cell Metab. 2019;30:e376.
Feranchak AP, Fitz JG, Roman RM. Volume‐sensitive purinergic signaling in human hepatocytes. J Hepatol. 2000;33:174–82.
Banales JM, Huebert RC, Karlsen T, Strazzabosco M, LaRusso NF, Gores GJ. Cholangiocyte pathobiology. Nat Rev Gastroenterol Hepatol. 2019;16:269–81.
Colombo C, Battezzati PM. Liver involvement in cystic fibrosis: primary organ damage or innocent bystander? J Hepatol. 2004;41:1041–4.
Li Q, Dutta A, Kresge C, Bugde A, Feranchak AP. Bile acids stimulate cholangiocyte fluid secretion by activation of transmembrane member 16A Cl(‐) channels. Hepatology. 2018;68:187–99.
Dutta AK, Woo K, Khimji AK, Kresge C, Feranchak AP. Mechanosensitive Cl‐ secretion in biliary epithelium mediated through TMEM16A. Am J Physiol Gastrointest Liver Physiol. 2013;304:G87–98.
Dutta AK, Khimji A‐K, Kresge C, Bugde A, Dougherty M, Esser V, et al. Identification and functional characterization of TMEM16A, a Ca2+‐activated Cl‐ channel activated by extracellular nucleotides, in biliary epithelium. J Biol Chem. 2011;286:766–76.
Guo J‐W, Liu X, Zhang T‐T, Lin X‐C, Hong YU, Yu J, et al. Hepatocyte TMEM16A deletion retards NAFLD progression by ameliorating hepatic glucose metabolic disorder. Adv Sci (Weinh). 2020;7:1903657.
Feranchak AP, Roman RM, Doctor RB, Salter KD, Toker A, Fitz JG. The lipid products of phosphoinositide 3‐kinase contribute to regulation of cholangiocyte ATP and chloride transport. J Biol Chem. 1999;274:30979–86.
Voss FK, Ullrich F, Münch J, Lazarow K, Lutter D, Mah N, et al. Identification of LRRC8 heteromers as an essential component of the volume‐regulated anion channel VRAC. Science. 2014;344:634–8.
Qiu Z, Dubin A, Mathur J, Tu B, Reddy K, Miraglia L, et al. SWELL1, a plasma membrane protein, is an essential component of volume‐regulated anion channel. Cell. 2014;157:447–58.
Fiorotto R, Strazzabosco M. Pathophysiology of cystic fibrosis liver disease: a channelopathy leading to alterations in innate immunity and in microbiota. Cell Mol Gastroenterol Hepatol. 2019;8:197–207.
Park JH, Ousingsawat J, Cabrita I, Bettels RE, Große‐Onnebrink J, Schmalstieg C, et al. TMEM16A deficiency: a potentially fatal neonatal disease resulting from impaired chloride currents. J Med Genet. 2021;58:247–53.
Li P, Hu M, Wang CE, Feng X, Zhao ZhuangZhuang, Yang Y, et al. LRRC8 family proteins within lysosomes regulate cellular osmoregulation and enhance cell survival to multiple physiological stresses. Proc Natl Acad Sci U S A. 2020;117:29155–65.
Schrem H, Klempnauer J, Borlak J. Liver‐enriched transcription factors in liver function and development. Part II: The C/EBPs and D site‐binding protein in cell cycle control, carcinogenesis, circadian gene regulation, liver regeneration, apoptosis, and liver‐specific gene regulation. Pharmacol Rev. 2004;56:291–330.
Gardner‐Stephen DA, Mackenzie PI. Liver‐enriched transcription factors and their role in regulating UDP glucuronosyltransferase gene expression. Curr Drug Metab. 2008;9:439–52.
Trefts E, Gannon M, Wasserman DH. The liver. Curr Biol. 2017;27:R1147–51.
Morio B, Panthu B, Bassot A, Rieusset J. Role of mitochondria in liver metabolic health and diseases. Cell Calcium. 2021;94:102336.
Strable MS, Ntambi JM. Genetic control of de novo lipogenesis: role in diet‐induced obesity. Crit Rev Biochem Mol Biol. 2010;45:199–214.
Lemos FO, Florentino RM, Lima Filho ACM, Dos Santos ML, Leite MF. Inositol 1,4,5‐trisphosphate receptor in the liver: expression and function. World J Gastroenterol. 2019;25:6483–94.
Stutts MJ, Canessa CM, Olsen JC, Hamrick M, Cohn JA, Rossier BC, et al. CFTR as a cAMP‐dependent regulator of sodium channels. Science. 1995;269:847–50.
Mansini AP, Peixoto E, Thelen KM, Gaspari C, Jin S, Gradilone SA. The cholangiocyte primary cilium in health and disease. Biochim Biophys Acta Mol Basis Dis. 2018;1864:1245–53.
Dutta AK, Woo K, Doctor RB, Fitz JG, Feranchak AP. Extracellular nucleotides stimulate Cl‐ currents in biliary epithelia through receptor‐mediated IP3 and Ca2+ release. Am J Physiol Gastrointest Liver Physiol. 2008;295:G1004–15.
Scudellari M. How iPS cells changed the world. Nature. 2016;534:310–2.
Musunuru K, Sheikh F, Gupta RM, Houser SR, Maher KO, Milan DJ, et al. Induced pluripotent stem cells for cardiovascular disease modeling and precision medicine: a scientific statement from the American Heart Association. Circ Genom Precis Med. 2018;11:e000043.
Giandomenico SL, Sutcliffe M, Lancaster MA. Generation and long‐term culture of advanced cerebral organoids for studying later stages of neural development. Nat Protoc. 2021;16:579–602.
Corbett JL, Duncan SA. iPSC‐derived hepatocytes as a platform for disease modeling and drug discovery. Front Med (Lausanne). 2019;6:265.
Jin M, Yi X, Liao W, Chen QI, Yang W, Li Y, et al. Advancements in stem cell‐derived hepatocyte‐like cell models for hepatotoxicity testing. Stem Cell Res Ther. 2021;12:84.
Akbari S, Sevinç GG, Ersoy N, Basak O, Kaplan K, Sevinç K, et al. Robust, long‐term culture of endoderm‐derived hepatic organoids for disease modeling. Stem Cell Reports. 2019;13:627–41.
Wang Z, Faria J, Penning LC, Masereeuw R, Spee B. Tissue‐engineered bile ducts for disease modeling and therapy. Tissue Eng Part C Methods. 2021;27:59–76.
Schaub JR, Huppert KA, Kurial SNT, Hsu BY, Cast AE, Donnelly B, et al. De novo formation of the biliary system by TGFbeta‐mediated hepatocyte transdifferentiation. Nature. 2018;557:247–51.
Clotman F, Jacquemin P, Plumb‐Rudewiez N, Pierreux CE, Van der Smissen P, Dietz HC, et al. Control of liver cell fate decision by a gradient of TGF beta signaling modulated by Onecut transcription factors. Genes Dev. 2005;19:1849–54.
Flynn DM, Nijjar S, Hubscher SG, de Goyet JV, Kelly DA, Strain AJ, et al. The role of Notch receptor expression in bile duct development and disease. J Pathol. 2004;204:55–64.
Amirneni S, Haep N, Gad MA, Soto‐Gutierrez A, Squires JE, Florentino RM. Molecular overview of progressive familial intrahepatic cholestasis. World J Gastroenterol. 2020;26:7470–84.
Riordan JR, Rommens JM, Kerem B‐S, Alon N, Rozmahel R, Grzelczak Z, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989;245:1066–73.
Chen JS, Sabir S, Al Khalili Y. Physiology, Osmoregulation and Excretion. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2021.